From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: A 6-month, multicenter, open-label tolerability switch study

Gemma Caterina Maria Rossi, Gian Maria Pasinetti, Francesco Sandolo, Marco Bordin, Paolo Emilio Bianchi

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). Methods: Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pressure (IOP), tear film break-up-time (TF-BUT), fluorescein staining and Glaucoma Symptom Scale (GSS) questionnaire were recorded at baseline and after 6 months. Results: Median interquartile range (IQR) IOP was 16 (IQR 15 18) mmHg at baseline and 16 (15 17) mmHg and 6 months. TF-BUT significantly improved (p <0.0001); the regression analysis found a negative association between TF-BUT changes and age at baseline and at month 6 (r = -0.32; p = 0.0082 and r = -0.31; p = 0.0085). Patients with no corneal fluorescein staining statistically increased after substitution (p = 0.04). Quality of life as examined by the GSS symptoms (SYMP) score statistically improved (p <0.0001), revealing an association between GSS SYMP score and age [coefficient -0.67, 95% confidence interval (CI) -1.13 to -0.21, p = 0.0005), superficial keratitis (coefficient -8.26, 95% CI -15.73 to -0.80, p = 0.031) and TF-BUT (coefficient 4.94, 95% CI 1.71 to 8.17, p = 0.003). Conclusion: Brinzolamide/timolol FC is associated with reduced topical discomfort and improved signs of ocular surface disease. The good tolerability and comfort of this FC might contribute to good patient adherence.

Original languageEnglish
Pages (from-to)2425-2431
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number16
DOIs
Publication statusPublished - Nov 2011

Keywords

  • brinzolamide/timolol fixed combination
  • efficacy
  • glaucoma
  • ocular surface
  • tolerability

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: A 6-month, multicenter, open-label tolerability switch study'. Together they form a unique fingerprint.

Cite this